CELEX: 62021TB0381
Language: en
Date: 2021-12-22 00:00:00
Title: Case T-381/21: Order of the General Court of 22 December 2021 — D&A Pharma v EMA (Action for annulment — Medicinal products for human use — Application for marketing authorisation for the medicinal product Hopveus — Non-renewal of a permanent scientific advisory group — No interest in bringing proceedings — Inadmissibility)

14.3.2022   
            
            
               EN
            
            
               Official Journal of the European Union
            
            
               C 119/46
            
         
      Order of the General Court of 22 December 2021 — D&A Pharma v EMA
      (Case T-381/21) (1)
      
      (Action for annulment - Medicinal products for human use - Application for marketing authorisation for the medicinal product Hopveus - Non-renewal of a permanent scientific advisory group - No interest in bringing proceedings - Inadmissibility)
      (2022/C 119/65)
      Language of the case: French
      
         Parties
      
      
         Applicant: Debregeas et associés Pharma (D&A Pharma) (Paris, France) (represented by: N. Viguié and D. Krzisch, lawyers)
      
         Defendant: European Medicines Agency (represented by: C. Bortoluzzi, H. Kerr, S. Marino and S. Drosos, acting as Agents)
      
         Re:
      
      APPLICATION pursuant to Article 263 TFEU seeking annulment of the decision of EMA not to renew the scientific advisory group on psychiatry within the Committee for Human Medicinal Products, revealed implicitly by the public call for expression of interest for experts to become members of EMA’s scientific advisory groups and the press release of EMA of 5 May 2021.
      
         Operative part of the order
      
      
                  1.
               
               
                  The action is dismissed as being inadmissible.
               
            
                  2.
               
               
                  There is no longer any need to adjudicate on the application for leave to intervene submitted by the European Parliament.
               
            
                  3.
               
               
                  Debregeas et associés Pharma (D & A Pharma) shall pay the costs.
               
            
                  4.
               
               
                  The Parliament shall bear its own costs relating to its application for leave to intervene.
               
            
         (1)  OJ C 329, 16.8.2021.